Compare BridgeBio Pharma Inc (BBIO) vs Berkshire Hathaway Inc Class B (BRK.B) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Berkshire Hathaway Inc Class B — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while Berkshire Hathaway Inc Class B trades at $491.3. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BBIO | BRK.B | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Financials |
52-Week High | $90.17 | $513.70 |
52-Week Low | $44.81 | $459.10 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
BRK.B trades at $496.79, up 0.63% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The stock is supported by strong analyst consensus with 57% buy ratings and no sell recommendations. Recent earnings reports highlight Berkshire Hathaway's diversified portfolio strength and consistent cash flow generation.
The outlook remains positive given institutional confidence and technical support near $494, though investors face risks from macroeconomic sensitivity and regulatory scrutiny. Upside potential exists if the company maintains its earnings momentum and capital allocation strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →
